Max Konig

@biorxivpreprint.bsky.social Precision targeting of autoreactive B cells in systemic lupus erythematosus using anti-9G4 idiotope synthetic immune receptor T cells
www.biorxiv.org/content/10.1...
Great work @maxkonigmd.bsky.social

Your Orwellian Government at work - National Cancer Institute Employees Can’t Publish Information on These Topics Without Special Approval #NIH
www.propublica.org/article/nati...

5.2 T'd Up T-Cells - RheumMadness Podcast In this episode, we dive in to the T'd Up T-cells region of RheumMadness 2025: the Innovation Invitational.  This is the first of a two-part conversation with the authors of the scouting reports ...

The #RheumMadness podcast is back! Join us as we discuss the T'd Up T-Cells Region, including:
-BiTEs with @maxkonigmd.bsky.social
-CD40L inhibitor for #Sjogren's with Duke rheum
-Abatacept for pre-RA with Allegheny rheum

rheummadness.buzzsprout.com/1465681/epis...

Not the first one treated. I believe on of the early SLE patients with CNS disease treated by iCell in China did very well.

Findings highlight ‘critical importance’ of infectious complications after CAR-T Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.Unique CAR-T-specific side effects — s...

Findings highlight ‘critical importance’ of infectious complications after CAR-T - read HemeOncToday interview with Kai Rejeski and me #medsky #CARTcells www.healio.com/news/hematol...

Thank you❤️

Targeting autoreactive TRBV9+ T cells using TRBV9xCD3 bispecific T cell engaging antibodies. Controlling ankylosing spondylitis and celiac disease without increasing the risk of infection? Let's go. Join us at Room 150, 3:00 PM. #precisionimmunotherapy #ACR24

#ACR24 with emerging pathology superstar Jin Liu. APS session done. More on BaiTEs to come.

Not sure who had the terrible idea to put up our talks on TRBV9 at the same time but in different rooms. No chance for debate. @acr-journals.bsky.social not good planning.

T Cell-Engaging Bispecific Antibodies to Target Autoreactive 9G4 Idiotope B Cells in Systemic Lupus Erythematosus - ACR Meeting Abstracts Background/Purpose: Chimeric antigen receptor (CAR)-T-cell therapies hold promise for systemic lupus erythematosus (SLE) but are critically limited by scalability and long-term safety (e.g., risk of t...

acrabstracts.org/abstract/t-c...

While at it, if you are interested in learning more about off-the-shelf precision immunotherapies for the treatment of lupus, please join our talk on 9G4xCD3 T cell-engaging antibodies during the SLE - Cellular Therapy Session at 3 PM. #ACR24

Precision Targeting of Autoreactive 9G4 B Cells in Systemic Lupus Erythematosus Using Engineered Chimeric Antigen Receptor (CAR)- and Chimeric T Cell Receptor (cTCR)-T Cells - ACR Meeting Abstracts Background/Purpose: The autoreactive B cell compartment in systemic lupus erythematosus (SLE) is characterized by expansion of B cells expressing immunoglobulin heavy variable gene 4-34 (IGHV4-34) B c...

acrabstracts.org/abstract/pre...

Congrats to Jin Liu for being awarded the ACR Emerging Investigator Excellence Award for her work on 9G4-targeted CAR/cTCR-T cells for the treatment of lupus. Join her talk today in the SLE - Cellular Therapy Session at 3 PM. #ACR24 #ProundMentorMoment

TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease - ACR Meeting Abstracts Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting ...

acrabstracts.org/abstract/trb...

Congrats to Steph Glavaris for being awarded the ACR Emerging Investigator Excellence Award for her work on T cell-engaging antibodies to deeply deplete TRBV9+, autoreactive T cells in ankylosing spondylitis and celiac disease. #ACR24 #ProundMentorMoment

Has anyone ever claimed CAR-T cell therapy is a cure-all?